NASDAQ:BIOC Biocept (BIOC) Stock Forecast, Price & News $1.12 +0.02 (+1.94%) (As of 10:10 AM ET) Add Compare Share Share Today's Range$1.11▼$1.1250-Day Range$0.82▼$1.6752-Week Range$0.80▼$28.26Volume7,688 shsAverage Volume708,642 shsMarket Capitalization$2.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Biocept (NASDAQ:BIOC) StockBiocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.Read More BIOC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOC Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comBiocept (NASDAQ:BIOC) Cut to Sell at StockNews.comSeptember 28, 2023 | americanbankingnews.comBiocept, Inc. (NASDAQ:BIOC) Short Interest UpdateOctober 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 22, 2023 | markets.businessinsider.comMaxim Group Remains a Hold on Biocept (BIOC)September 21, 2023 | finance.yahoo.comEnrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesSeptember 11, 2023 | benzinga.comThinking about buying stock in Tivic Health Systems, Axcella Health, Biocept, Aravive, or Uranium Royalty Corp?September 9, 2023 | marketwatch.comBiocept Shares Double While Plus Therapeutics Shares Sink on Licensing AgreementSeptember 8, 2023 | msn.comBiocept and Plus Therapeutics collaborate in battle against leptomeningeal metastasesOctober 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 8, 2023 | finance.yahoo.comPlus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration AssaySeptember 5, 2023 | finance.yahoo.comBiocept to Participate in the H.C. Wainwright Global Investment ConferenceAugust 25, 2023 | businesswire.comBiocept to Hold Business Update Conference Call on August 30, 2023August 23, 2023 | thestreet.comBiocept (BIOC) Stock Popping on Blue Cross Blue Shield PartnershipAugust 17, 2023 | markets.businessinsider.comBiocept (BIOC) Gets a Hold from Maxim GroupAugust 14, 2023 | finance.yahoo.comBiocept Reports Second Quarter 2023 Financial ResultsAugust 14, 2023 | finance.yahoo.comBiocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer ConferenceAugust 1, 2023 | finance.yahoo.comBiocept, Inc. (NASDAQ:BIOC) Is Expected To Breakeven In The Near FutureJuly 13, 2023 | finance.yahoo.comBiocept Announces the Passing of Board Chair M. Faye WilsonJune 22, 2023 | marketwatch.comWi-Fi Hotspot Devices Market by Technology Advancements and Growth Outlook to 2030 | Preanalytix, Roche, BioceptJune 21, 2023 | proactiveinvestors.comBiocept appoints Antonino Morales as president and chief executive... Biocept appoints Antonino Morales as president and chief executive...June 20, 2023 | finance.yahoo.comBiocept Names Antonino Morales as President and Chief Executive OfficerJune 14, 2023 | finance.yahoo.comBiocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023June 5, 2023 | proactiveinvestors.comBiocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastasesJune 5, 2023 | finance.yahoo.comScientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus CytologyMay 26, 2023 | benzinga.comBiocept shares are trading lower after the company announced pricing of a $5 million underwritten public offering.May 26, 2023 | marketwatch.comBiocept Shares Sink After Public Offering PricingMay 25, 2023 | msn.comBiocept stock surges on pricing $5.0M stock offeringSee More Headlines Receive BIOC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOC Company Calendar Last Earnings8/14/2023Today10/03/2023Next Earnings (Estimated)11/20/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC CUSIPN/A CIK1044378 Webwww.biocept.com Phone(858) 320-8200Fax858-320-8225Employees50Year Founded1993Profitability EPS (Most Recent Fiscal Year)($58.4549) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,090,000.00 Net MarginsN/A Pretax Margin-564.02% Return on Equity-468.87% Return on Assets-118.41% Debt Debt-to-Equity Ratio2.88 Current Ratio1.81 Quick Ratio1.70 Sales & Book Value Annual Sales$25.86 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$15.60 per share Price / Book0.07Miscellaneous Outstanding Shares2,630,000Free Float2,584,000Market Cap$2.89 million OptionableOptionable Beta0.69 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Antonino Morales (Age 67)CEO, Pres & Director Comp: $439.43kMr. Darrell Taylor Esq. (Age 58)Chief Legal Officer, Chief Compliance Officer, Corp. Sec. & Registered In-House Counsel Comp: $432.27kDr. Soon Kap Hahn Ph.D.FounderMr. Rob WalshVP & ControllerDr. Philippe J. Marchand Ph.D. (Age 60)Chief Operating Officer Mr. Pavel TsinbergDirector of Technology Devel.Mr. David S. Moskowitz R.Ph.MBA, VP of Strategy & Corp. CommunicationsDr. Veena M. Singh (Age 48)Sr. Medical Director More ExecutivesKey CompetitorsAclarionNASDAQ:ACONOpGenNASDAQ:OPGNAkuminNASDAQ:AKUPalisade BioNASDAQ:PALINanoVibronixNASDAQ:NAOVView All CompetitorsInstitutional OwnershipBoothbay Fund Management LLCBought 23,529 shares on 8/15/2023Ownership: 3.988%Citadel Advisors LLCSold 100 shares on 8/15/2023Ownership: 0.000%Anson Funds Management LPBought 44,861 shares on 8/14/2023Ownership: 7.604%Simplex Trading LLCSold 500 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions BIOC Stock - Frequently Asked Questions Should I buy or sell Biocept stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares. View BIOC analyst ratings or view top-rated stocks. How have BIOC shares performed in 2023? Biocept's stock was trading at $15.90 at the beginning of 2023. Since then, BIOC shares have decreased by 93.1% and is now trading at $1.10. View the best growth stocks for 2023 here. Are investors shorting Biocept? Biocept saw a increase in short interest in September. As of September 15th, there was short interest totaling 610,600 shares, an increase of 3,692.5% from the August 31st total of 16,100 shares. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is presently 0.3 days. Currently, 23.3% of the company's stock are sold short. View Biocept's Short Interest. When is Biocept's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023. View our BIOC earnings forecast. How were Biocept's earnings last quarter? Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings results on Monday, August, 14th. The medical research company reported ($3.50) EPS for the quarter. The medical research company had revenue of $0.59 million for the quarter. When did Biocept's stock split? Biocept shares reverse split on the morning of Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Michael Nall's approval rating as Biocept's CEO? 4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend. What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST). What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." How do I buy shares of Biocept? Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $1.10. How much money does Biocept make? Biocept (NASDAQ:BIOC) has a market capitalization of $2.89 million and generates $25.86 million in revenue each year. The medical research company earns $-32,090,000.00 in net income (profit) each year or ($58.4549) on an earnings per share basis. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225. This page (NASDAQ:BIOC) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biocept, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.